What We Do
The healing of wounds can be difficult for some patients, particularly where chronic inflammation and increased oxidative stress are involved in the wound healing impairment. Hydrogels are promising materials as wound healing dressings, particularly if they remain adhered to the wound and could also release therapeutic factors to the wound bed over time. We have developed the first bio-inert adhesive hydrogel delivery system that offers controlled delivery of therapeutics to promote healing while avoiding the unwanted inflammatory response that accompanies other brand wound dressings.
A gentle adhesive wound dressing hydrogel that provides superior healing to patients.
In the US, 1 patient with diabetes will develop a difficult to heal ulcer every 1.2 seconds. Half of these ulcers will get infected and ultimately lead to surgical amputations, which happen every 20 seconds. They cost more than $1.5 billion in health care in our country every year, and there is no clear treatment in site. They are devastating to patients, with the 5 year mortality being worse than any cancer. Advanced wound care options are limited.
GelSana designs novel wound care dressings. Ultimately our customer is the patient or clinician that needs extra care in healing a difficult wound. Patients and clinicians will be able to purchase these gels either through their health insurance or be provided as an OTC product.
Global wound care market is ~$20B, US advanced wound care market is $2.6B. This includes biologics and wound dressings.
Smith + Nephew: Oasis wound matrix, a decellularized porcine tissue matrix. Regranex, a growth factor containing ointment.
Cardinal Health: Aquaflo, a silicon gel to keep wounds moist.
Other hydrogel wound dressings (Intrasite gel, SeaSorb)
Go to Market Strategy
Initial product is an inert hydrogel that aids in the healing process, and that can be classified as a medical device. Initial product is an inert hydrogel that aids in the healing process, and that can be classified as a medical device.
We have received pre-seed funding from Innosphere fund. We have one granted patent and 4 patent applications pending. We have exciting data showing efficacy in mice.